โก Quick Summary
This review explores the promising field of antibody-drug conjugates (ADCs), highlighting their potential as targeted cancer therapies while addressing challenges such as toxicity and resistance development. The authors emphasize the importance of target selection and innovative strategies to enhance ADC efficacy and safety.
๐ Key Details
- ๐ Focus: Antibody-drug conjugates (ADCs) in cancer therapy
- ๐งฉ Challenges: Off/on-target toxicity and resistance
- โ๏ธ Strategies discussed: Multitarget approaches, pH-dependent antibodies, masked peptide technologies
- ๐ฌ Technologies highlighted: Single-cell sequencing, artificial intelligence (AI)
- ๐ก Innovations: Linker-payload chemistry and combination therapies
๐ Key Takeaways
- ๐ฏ ADCs combine the specificity of monoclonal antibodies with potent cytotoxic agents.
- โ ๏ธ Challenges include managing off-target effects and developing resistance.
- ๐ Comprehensive antigen profiling is crucial for effective target selection.
- ๐ค Advanced technologies like AI can optimize the selection process.
- ๐งฌ Innovations in linker-payload chemistry may enhance therapeutic windows.
- ๐ ADC applications could extend beyond oncology with ongoing research.
- ๐ Combination therapies are explored as a means to improve ADC effectiveness.
๐ Background
Antibody-drug conjugates (ADCs) are an innovative class of cancer therapeutics that merge the targeting capabilities of monoclonal antibodies with the destructive power of cytotoxic drugs. While ADCs hold great promise for treating various cancers, their development is fraught with challenges, particularly concerning toxicity and the emergence of resistance. Understanding these complexities is essential for advancing ADC technology and improving patient outcomes.
๐๏ธ Study
This review article delves into the current landscape of ADC development, focusing on the intricacies of target selection and the engineering of antibodies. The authors discuss various strategies aimed at enhancing the efficacy and safety of ADCs, including the use of multitarget approaches and innovative technologies that can help mitigate adverse effects.
๐ Results
The review highlights several promising strategies for improving ADC performance. These include the implementation of pH-dependent antibodies and masked peptide technologies, which can enhance targeting precision and reduce toxicity. Furthermore, the integration of advanced technologies like single-cell sequencing and AI is emphasized as a means to refine target selection and improve therapeutic outcomes.
๐ Impact and Implications
The insights gained from this review could significantly influence the future of cancer treatment. By addressing the challenges associated with ADCs and exploring innovative strategies, researchers can pave the way for more effective and safer cancer therapies. The potential expansion of ADC applications beyond oncology also opens new avenues for research and treatment, promising a brighter future for patients.
๐ฎ Conclusion
This review underscores the transformative potential of antibody-drug conjugates in cancer therapy. By focusing on target selection and employing innovative strategies, the field can overcome existing challenges and enhance the efficacy of ADCs. Continued research and development in this area are crucial for realizing the full potential of ADCs in improving patient care and outcomes.
๐ฌ Your comments
What are your thoughts on the advancements in antibody-drug conjugates? We would love to hear your insights! ๐ฌ Share your comments below or connect with us on social media:
The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.
Abstract
Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Despite their therapeutic potential, the use of ADCs faces significant challenges, including off/on-target toxicity and resistance development. This review examines the current landscape of ADC development, focusing on the critical aspects of target selection and antibody engineering. We discuss strategies to increase ADC efficacy and safety, including multitarget approaches, pH-dependent antibodies, and masked peptide technologies. The importance of comprehensive antigen expression profiling in both tumor and normal tissues is emphasized, highlighting the role of advanced technologies, such as single-cell sequencing and artificial intelligence (AI), in optimizing target selection. Furthermore, we explore combination therapies and innovations in linkerโpayload chemistry, which may provide approaches for expanding the therapeutic window of ADCs. These advances pave the way for the development of more precise and effective cancer treatments, potentially extending ADC applications beyond oncology.
Author: [‘Liu H’, ‘Zeng H’, ‘Qin X’, ‘Ning W’, ‘Xu L’, ‘Yang S’, ‘Liu X’, ‘Luo W’, ‘Xia N’]
Journal: Protein Cell
Citation: Liu H, et al. The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts. The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts. 2025; (unknown volume):(unknown pages). doi: 10.1093/procel/pwaf002